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 We used the quantitative receptor autoradiographic method 
with a radioligand of [ 125I ]lysergic acid diethylamide 
([125I]LSD) to quantitate platelet serotonin (5-HT)2A recep-
tors in affective disorders. Specific binding of [125I]LSD to 
human platelet pellet sections was saturable, and of high 
affinity and single. Both ketanserin and spiperone, 5-HT2A 
selective ligands, inhibited [125I]LSD binding to human plate-
let pellets with high potency (IC50 values of 0.15 and 0.19 
nM, respectively), whereas 5-HT and paroxetine, selective 5-
HT re-uptake inhibitors, inhibited binding with a very low 
potency. These data confirmed that binding sites of human plate-
let pellets specifically labelled by [125I] LSD were 5-HT2A receptors. 
 The number of 5-HT2A receptors (Bmax of [ 125I] LSD bind-
ing) of human platelets obtained from drug-free depressed 
patients was significantly higher than those of healthy vol-
unteers. There were no statistical differences in the number 
of 5-HT2A receptors between depressed patients with and 
without suicidal behaviors. The increased number in platelet 
5-HT2A receptotrs may indicate a hyperfunction of the central 
5-HT2A receptors. The method with human platelets pellet 
sections we used is simple and sensitive for investigating 
platelet 5-HT2A receptors, a diagnostic and therapeutic 
marker in depressive disorders, in the clinical research.
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Introduction 
  Affective disorders are thought to be associated 
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with dysfuctions in the central serotonergic neurons. 
Concentrations of serotonin (5-HT) and 5-hydroxyindole-
acetic acid (5-HIAA) was reduced in the cerebrospinal 
fluid of drug-free depressive patients'), and in the post-
mortem brains of depressive and suicidal patients"). A 
decreased number of 5-HT transporter binding sites 
was also noted in the postmortem brains of depressive 
and suicidal patients") . Interestingly, Arora and 
Meltzer found an increase in the density of 5-HT2A re-
ceptor binding sites in the postmortem brains of de-
pressive and suicidal patients'). 
 As a similarity in binding charcteristics with 5-HT2A 
ligands between human blood platelets and frontal cor-
tex tissues was reported"),") and a nucleotide sequence 
of human platelet 5-HT2A cDNA was found to be iden-
tical to that of human frontal cortex'), human platelets 
are attracting attention as a model for the central 5-
HT neurons. Changes in the density of 5-HT2A recep-
tors and 5-HT transpoter binding sites were detected 
in membrane preparations of blood platelets obtained 
from patients with affective disorders' 1),12),19). The 5-HT2A 
ligand-binding method with membrane preparations 
seems inadequate to investigate 5-HT2A receptor bind-
ing sites in human platelets of patients with affetive 
disorders, since it needs a large volume of blood (i.e, 
30 ml). In fact, the binding characteristic in human 
platelets may vary from human blood-sampling 
processes""'). Himeno and Saavedra found that the 
quantitaive receptor autoradiographic method with 
patelet-pellet sections can detect 5-HT receptor binding 
sites in platelets obtained from a small volume of 
human blood (1.0 ml)11),17). Therefore, taking advantage 
of the high sensitivity, to characterize platelet 5-HT2A 
receptors of patients with affective disorders, we used 
the quantitaitive receptor autoradiographic method 
with a radioligand of [125I] lysergic acid diethylamide 
([1211]LSD) in the present study.
Materials and Methods 
Preliminary experiments for characterizing human platelet 
5-HT2A receptors 
 Basic experiments to quantitate human platelet 5-HT2A 
receptors were performed with five healthy volunteers 
with no histories of psychiatric and neurologic disor-
ders. All subjects were in good physical health, and 
were free from psychotropic medications. Informed 
consent of healthy volunteers was obtained after the 
study procedures had been fully explained.
Depressive patients and normal controls 
 Outpatients with depressive disorder were recruited 
in our University-affiliated clinics. All patients enrolled 
in the protocol met ICD-10 classification of mental and 
behavioral disorders: diagnostic criteria for research"' 
ICD-10/DCR for mood (affective) disorders as deter-
mined by interviews with plural psychiatrists. All de-
pressed patients were determined to be physically 
healthy on the basis of their medical histories, physi-
cal examination, and routine laboratory tests. Clinical 
ratings were performed in close juxtaposition to the 
venipuncture by staff who were blind to the binding 
results. In addition, binding experiments were also per-
formed by other staff who were blind to the clinical 
ratings. Patients diagnosed with depressive disorder 
according to ICD-10/DCR criteria were studied. Eight 
depressive patients(male: 6, female: 2) with no history 
of neurologic disorders ranged in age from 26 to 69 
years. The mean age of the subjects was 45.1±5.2 
(mean± SEM) years. Depressive patients were in good 
physical health, and were free for at least 6 months 
from psychotropic medication. Subjects for normal 
controls (male: 4, female: 1) with no history of psychi-
atric or neurologic disorders ranged in age from 25 to 
45 years. The mean age of the subjects was 36.8-L3.4 
years. Control subjects were in good physical health 
and were free from psychotropic medication. There 
was no statistical differences in age and sex between 
the two groups. Informed consent of depressive pa-
tients and normal controls was obtained after the 
study procedures had been fully explained. 
  The categories of ICD-10 system for these patients 
were F31.5 bipolar affective disorder, current episode 
of severe depression with psychotic symptoms, F32.1 
moderate depressive episode, F33.1 recurrent depres-
sive disorder, current episode moderate, F33.2 recur-
rent depressive disorder, current episode severe with-
out psychotic symptoms, and F33.3 recurrent depressive
disorder, current episode severe with psychotic symp-
toms. 
Clinical assessment of the severity of patient's current de-
pressive symptoms 
  The severity of the patient's current depressive 
symptoms was assessed using the Hamilton Depression 
Scale's' (HAMD).
Quantitaitive receptor autoradiographic method with 
[125I]LSD 
 We drew whole blood from normal subjects via a 
21-gauge needle into 5 ml vacuum glass tubes con-
taining EDTA-2Na. Platelet-rich plasma (PRP) was ob-
tained by centrifugation of blood at 180 X g for 15 min 
at room temperature. Following centrifugation, we re-
moved PRP to conical polypropylene tubes containing 
20 u 1 of M-1 embedding matrix. We centrifuged the 
tubes at 1200 X g for 8 min at room temperature. After 
discarding the supernatant, we slowly added 250 u 1 of 
M-1 embedding matrix on top of the pellet, together 
with a thin wooden stick. The tubes were frozen in 
isopentane on dry ice. We separated the pellets by 
lightly warming the tubes and pulling the stick. The 
frozen platelet pellet was mounted on a cryostat chuck 
(-20°C) with mounting medium and was sectioned at 
20 u m thickness. 
 Triplicate sections were preincubated for 15 min at 
room temperature in buffer solution(50 mM Tris-HCI, 
120 mM NaCl, 5 mM, 1 MM MgC12, 0.05% ascorbate, 
pH 7.4). After preincubation, sections were incubated 
with [12-51]LSD (0.08 nM-3.64 nM) in the presence or 
absence of competing ligands for 15 min, 30 min, 60 
min or 180 min, at 4 °C, 23°Cor 37Cin buffer solution 
(50 mM Tris-HCI, 120 mM NaCl, 5 mM, 1 mM MgC12, 
0.05% ascorbate, pH 7.4). Slices were then washed at 
room temperature, dipped three times for 1 min each 
in fresh ice-cold buffer(50 mM Tris-HCI, 120 mM NaCl, 
5 mM, 1 MM MgC12, 0.05% ascorbate, pH 7.4) or three 
times for 3 min each in fresh ice-cold buffer and for 1 
sec in ice-cold distilled water. Slide sections were then 
dried under a stream of cold air, and the 
radioactivities of these sections were analyzed using 
the imaging plate system') . Autoradiographic 
[1251]micro-scales(Amersham) were used for standards. 
A Scatchard analysis was performed by the method of 
least squares. 
 In the inhibition study we used a single 0.35 nM 
[ 1251] LSD concentration, and six concentrations( 10-'° to 
10-5 M) of unlabeled ketanserin, spioerone, 5-HT, and
paroxetine. Ketanserin and spiperone are the 5-HT,, se-
lective ligands, and paroxetine is a selective 5-HT 
reuptake inhibitor.
Data analysis 
  The two-tailed Student's t-test was used to contrast 
values for the 5-HT2A receptor binding parameters be-
tween patients and normal controls or patient sub-
groups.
Results 
Experimental conditions for in vitro quantitation of [1251] 
LSD binding in human platelets 
The incubation temperatures for the [125I]LSD bind-
ing were set at either VC, 23C, or 371C (Fig.1). 
Specific binding of [ 1251] LSD at an incubation tempera-
ture of 37°C was two to three times higher than that 
at 4°C or 23°C. The ratio of specific/total binding of 
 1211]LSD at 37°C was 50-60 %. 
 The incubation times for the [ 1211 ]LSD binding were 
at 15 min, 30 min, 60 min, or 180 min (Fig.2). 
Specific binding of [ 1251] LSD at an incubation time of 
60 min was much higher than that at 15 min, 30 min, 
or 180 min. The ratio of specific/total binding of[ 1251] 
LSD at an incubation time of 60 min was also highest.
Fig.2. Incubation time of in vitro quantitation of [125I]LSD 
binding in human platelet pellet sections. 
Sections were incubated with [125I]LSD (0.22 nM) in the pres-
ence or absence of competing ligands for 15 min, 30 min, 60 
min or 180 min, at 37C in buffer solution. Each point repre-
sents the specific binding. Specific binding of [125I]LSD at an 
incubation time of 60 min was much higher than that at 15 
min, 30 min, or 180 min . The ratio of specific/total binding 
of [ 1251] LSD at an incubation time of 60 min was also high-
est. 
Two different washing times were used. A washing 
time of 3 min in fresh ice-cold buffer showed a much 
higher specific binding of [ 125I] LSD than a washing 
time of 9 min (Fig.3).
Fig.l. Incubation temperature of in vitro quantitation of 
[125I]LSD binding in human platelet pellet sections. Sections 
were incubated with [1251]LSD (0.22 nM) in the presence 
(nonspecific binding)or absence(total binding) of competing 
ligands for 60 min , at 4 C, 23Cor 371C in buffer solution(50 
mM Tris-HCI, 120 mM NaCl, 5 mM, 1 MM MgCl2, 0.05% 
ascorbate, pH 7.4). Specific binding of [125I]LSD at an incuba-
tion temperature of 37°C was two to three times higher than 
that at 4°C or 23°C. The ratio of specific/total binding of 
[1211]LSD at 37Cwas 50-60 %.
Fig.3. Washing time of in vitro quantitation of [125I]LSD 
binding in human platelet pellet sections. Sections were in-
cubated with [ 1251] LSD (0.22 nM) in the presence or absence 
of competing ligands for 60 min, at 37 °C in buffer solution. 
Slices were then washed at room temperature, dipped three 
times for 1 min each in fresh ice-cold buffer(50 mM Tris-HCI, 
120 mM NaCI, 5 mM, 1 MM MgC12, 0.05% ascorbate, pH 7.4) 
or three times for 3 min each in fresh ice-cold buffer and for 
1 sec in ice-cold distilled water. A washing time of 3 min in 
fresh ice-cold buffer showed a much higher specific binding 
of [ 125I] LSD than a washing time of 9 min.
Fig.4. Autoradiographic images of 11LSD binding inhuman 
platelet pellet sections 
Autoradiographic images of sections incubated with 0.35 nM 
 [1251]LSD in the absence(A) or presence(B) of 1 u M unlabeled 
ketanserin. 
Based on these results, we chose a [19]LSD binding 
condition of incubation temperature of 37°C and incu-
bation time of 60 min, with three washes of 1 min 
each in fresh ice-cold buffer and then 1 sec in ice-cold 
distilled water. Under the binding condition, we ob-
served considerable amounts of specific [125I]LSD bind-
ing to pellet sections of human platelets (Fig. 4). 
Saturation study and Scatchard analysis of [125I]-LSD 
binding to human platelet pellet sections 
 After preincubation, sections were incubated with 
['211]LSD (0.08 nM-3.64 nM) in the presence or ab-
sence of 1 p M ketanserin for 60 min at 37°C in buffer 
solution. Specific binding of [1251]LSD to human plate-
let pellet sections was saturable and of high affinity.
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Fig.5. Saturation study and Scatchard analysis of [1211]LSD 
binding to human platelet pellet sections. 
Specific binding of [125I]LSD to human platelet pellet sections 
was saturable and of high affinity. Each point represents the 
specific binding. The Scatchard analysis of these data demon-
strated a correlation coefficient close to unity, indicating a 
single binding site.
The Scatchard analysis of these data demonstrated a 
correlation coefficient close to unity, indicating a sin-
gle binding site (Fig.5).
Inhibition of specific binding of [125I]LSD to human 
platelet pellet sections (Table 1)
 Both ketanserin and spiperone, the 5-HT,, selective 
ligands, inhibited [125I]LSD binding to human platelet 
pellets with a high potency, with IC50 values of 0.15 
and 0.19 nM, respectively, whereas 5-HT and 
paroxetine (selective 5-HT reuptake inhibitor) inhib-
ited binding with a very low potency (IC, values 
>1000 nM). This data confirms that the binding sites 
of human platelet pellets labelled by [1151 ] LSD are 5-
HT,,, receptors.
Table 1. Inhibition of specific binding of [t25I]LSD to human 
platelet pellet sections. 
   Inhibitor IC5o (nM) 
   ketanserin 0.15 
   spiperone 0.19 
   serotonin >1000 
   paroxetine >1000
In the inhibition study we used a single 0.35 nM [125I]LSD 
concentration, and six concentrations( 10` to 10-5 M)of 
unlabeled ketanserin, spiperone, 5-HT, and paroxetine. 
Ketanserin and spiperone are the 5-HT,, selective ligands, 
and paroxetine is a selective 5-HT reuptake inhibitor. 
Clinical assesment of the severity of patient's current de-
pressive symptoms (Table 2) 
 The severity of the depressive state of these patients 
at the time of blood sampling before treatment was 
just over moderate severity, with patients receiving a 
HAMD score (17 items) of 17-37 points (25.4± 2.9, me 
an±SEM). 
Binding parameters(Kd and Bmax)of platelet [125I]LSD 
binding in the depressive patient group and the control 
group were calculated by Scatchard analysis 
 The binding parameters of platelet [1211 ] LSD binding 
in these two groups at the time of blood sampling be-
fore treatment were calculated by Scatchard analysis. 
The mean (±SEM) Kd of ['21I]LSD binding for the 
control group was 0.87±0.06 nM (n=5), which was 
not significantly different from that of depressive
Table 2. Clincal Characteristics of Depressive Patients and Normal Controls 
Subject Diagnosis HAMD Histories of Suicidal ideas 
No. Age, sex (ICD-10) (17i terns) suicide attempts in this epidode 
Depressive Patients 
1 32, m F33.1 17 - -
2 45, m F33.1 21 - -
3 26, f F33.1 19 + -
4 63, m F32.1 19 - -
5 44, m F33.3 22 + + 
6 47, m F31.5 37 + + 
7 35, m F33.2 37 - + 
8 69, f F31.5 31 + + 
 Mean±SEM 45.1 ±5. 2 25.4±2. 9 
Normal Control 
1 37, m 
2 25, f 
3 42, m 
4 35, m 
5 45, m 
 Mean±SEM 36.8±3.4 
F31.5: bipolar affective disorder, current episode of severe depression with psychotic symptoms,F32.1: mod-
erate depressive episode, F33.1: recurrent depressive disorder, current episode moderate, F33.2: recurrent 
depressive disorder, current episode severe without psychotic symptoms, F33.3: recurrent depressive disor-
der, current edisode severe with psychotic symptoms, HAMD: Hamilton Depression Scale
patient group, 1.04 ± 0.08 nM (n = 8). The Bmax of 
['25I] LSD binding was significantly increased in the 
patient group (5.52±0.46 fmol/mg) compared to the 
control group (3.13±0.20 fmol/mg, p < 0.01) (Table 3, 
Fig.6). 
Bmax of [125I]LSD binding and the HAMD score for 
eight depressive patients
 A comparison of the Bmax of [ 125I] LSD binding for 
the eight depressive patients free from psychotropic 
medication for at least 6 months with the HAMD 
scores at the time of blood sampling before treatment 
showed no significant correlation (r= 0.16, p=0.56, 
Fig.7).
Fig.6. Binding parameters(Kd and Bmax)of platelet [125I]LSD 
binding in depressive patients free from psychotropic medica-
tion for at least 6 months and the normal controls. The bind-
ing parameters of platelet [125I]LSD binding in these two 
groups at the time of blood sampling before treatment were 
calculated by Scatchard analysis. The mean (±SEM) Kd of 
['25I] LSD binding for the control group was 0.87±0.06 nM 
(n=5), which was not significantly different from the that of 
depressive patient group, 1.04±0.08 nM (n=8). The Bmax of 
[1251]LSD binding was significantly increased in the patient 
group (5.52±0.46 fmol/mg) compared to the control group (
3.13±0.20 fmol/mg, p<0.01).
Fig.7. The Bmax of [125I]LSD binding and the HAMD scores 
for eight depressive patients free from psychotropic medica-
tion for at least 6 months. A comparison of the Bmax of 
[1211]LSD binding for the eight depressive patients free from 
psychotropic medication for at least 6 months with the 
HAMD scores at the time of blood sampling before treatment 
showed no significant correlation(r=0.16, p=0.56).
Table 3. Binding parameters(Kd and Bmax)of platelet [125I]LSD binding 
in the depressive patients, free from psychotropic medication at leastsix 
months and the normal controls 
Subject Depressive Patients Normal Controls 
No. Kd Bmax Kd Bmax 
            (nM) (f mo l /mg) OM) (f mol /mg) 
1 0.89 5.08 0.77 2.70 
2 1.16 3.85 0.93 3.10 
3 1.09 7.50 0.77 3.86 
4. 0.68 4.94 1.04 2.90 
5 1.22 6.40 0.84 3.10 
6 0.94 4.70 
7 0.96 7.10 
8 1.39 4.60 
Mean±SEM 1.04± 0.08 5.52± 0.46" 0.87± 0.05 3.13-±- 0.20 
L ** p (0 .01, two-tailed Student's t-test, as compared to normal controls
Bmax of [125I]LSD binding for patients with suicidal be-
havior and without suicidal behavior(Fig.8)
 In the eight depressive patients, four had past histo-
ries of suicidal attempts (Table 2). In addition, four of 
the patients had suicidal ideas, show over position 2 in 
the item "suicide" of HAMD, at the time of blood sam-
pling (Table 2). 
 The Bmax for the patient subgroup with histories of 
suicidal attempts was 5.80±0.70 fmol/mg (mean ± SEM, 
n=4), which was not significantly different from the 
patient subgroup without histories of suicidal attempts 
5.24±0.68 fmol/mg(mean±SEM, n=4). The Bmax for 
the patient subgroup with suicidal ideas at the time of 
blood sampling was 5.70 ± 0.62 fmol/mg(mean ± SEM, 
n=4), which was also not significantly different from 
the patient subgroup without suicidal ideas at the time 
of blood sampling 5.34±0.77 fmol / mg (mean ± SEM, 
n=4). The Bmax for every patient subgroup was sig-
nificantly increased compared to the con-
trol group (p <0.05). 
 The Kd for the patient subgroup with 
histories of suicidal attempts was 1.16 ± 0.10 
nM (mean ± SEM, n=4), which was not 
significantly different from the patient sub-
group without histories of suicidal attempts 
0.92±0.10 nM(mean ±SEM, n=4). The Kd 
for the patient subgroup with suicidal ideas 
at the time of blood sampling was 1.13± 
0.11 nM(mean ±SEM, n=4), which was 
also not significantly different from the pa-
tient subgroup without suicidal idea at the 
time of blood sampling 0.96±0.11 nM (mean 
±SEM, n=4).
Platelet 5-HT2A receptor binding and scores on Hamilton's 
rating scale for depression (HAMD) after treatment in 
two cases 
 Case No.5 44-year-old man , head of the office 
Diagnosis: F33.3 recurrent depressive disorder, current 
episode severe with psychotic symptoms 
 The patient had his first depressive episode at age 
25, and at age 27, he had his second depressive epi-
sode. Since then, he has had some minor depressive 
episodes without any difficulties in business. He had 
no history of psychiatric treatment or psychotropic 
medication. In the present episode, at age 44, after he 
was very busy on business, he had depressive symp-
toms including a depressive mood, insomnia, and appe-
tite loss. One month later, his follower caused a traffic
Fig.8. The Bmax of [125I] LSD binding for patients with suicidal behavior and without suicidal behavior. 
The Bmax for the patient subgroup with histories of suicidal attempts was 5.80±0.70 fmol/ mg (mean ±SEM, 
n=4), which was not significantly different from the patient subgroup without histories of suicidal attempts 5. 
24±0.68 fmol/mg(mean ±SEM, n=4). The Bmax for the patient subgroup with suicidal ideas at the time of 
blood sampling was 5.70 ±0.62 fmol/mg(mean ±SEM, n=4), which was also not significantly different from the 
patient subgroup without suicidal ideas at the time of blood sampling 5.34 ±0.77 fmol/mg(mean ±SEM, n=4). 
Depression(SA): the patient subgroup with histories of suicidal attempts, Depression(-SA): the patient subgroup 
without histories of suicidal attempts. Depression(SI): the patient subgroup with suicidal ideas at the time of 
blood sampling, Depression(-SI): the patient subgroup without suicidal ideas at the time of blood sampling.
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Fig.9. Repeated analysis of platelet 5-HT2A receptor binding 
and the HAMD rating after treatment in the case of depres-
sive patient No.5. His depressive symptoms subsided in re-
sponse to the antidepressant treatment. The Bmax of platelet 
[125I]LSD binding showed a gradually decrease, corresponding 
to the decreased HAMD number, which was also in response 
to the antidepressant treatment(maprotiline maximum dose 
60 mg/day). A comparison of the Bmax of [1211]LSD binding 
and the HAMD score demonstrated a significant linear corre-
lation (r= 0.99, p=0.00002). 
accident. He blamed himself for that accident and felt 
severe guilt. He also felt that he was subject to a po-
liceman's superintendence. One month later he made a 
suicidal attempt (hanging), and he visited our psychi-
atric clinic and was admitted to our psychiatric ward 
the same day. After admission, his HAMD score was 
evaluated and a platelet [ 125I] LSD binding assay was 
performed every week. At the first week of admission, 
flunitrazepam was prescribed. In addition, at the sec-
ond week, an antidepressant treatment(maprotiline 30 
mg/day) was started. His depressive symptoms sub-
sided in response to the antidepressant treatment. The 
Bmax of platelet [125I]LSD binding showed a gradually 
decrease, corresponding to the decreased HAMD score, 
which was also in response to the antidepressant 
treatment(maprotiline maximum dose 60 mg/day). A 
comparison of the Bmax of [ 125I] LSD binding and the 
HAMD score demonstrated a significant linear correla-
tion (r=0.99, p=0.00002, Fig.9.).
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Fig.10. Repeated analysis of platelet 5-HT2A receptor binding 
and the HAMD rating after treatment in the case of depres-
sive patient No.9. After the start of treatment with an experi-
mental new drug(double blind study), his depressive symp-
toms improved initially, but from the sixth week of 
admission they became worse. Correlatively, the Bmax of 
platelet [125I] LSD binding decreased at first and then in-
creased. A comparison of the Bmax of [ 125I] LSD binding and 
the HAMD scores also demonstrated a significant linear cor-
relation (r=0.71, p=0.02). 
Case No.9 35-year-old man, cook 
Diagnosis: F31.3 bipolar affective disorder, current epi-
sode mild or moderate depression 
 The patient had his first depressive episode at age 
23, and at age 24, he had first hypomanic episode. At 
age 25, he had his second depressive episode, and at 
age 27, he had his third depressive episode. In the pre-
sent episode, at age 34, he had depressive symptoms 
that included a depressive mood and low self confi-
dence, because he was worried about his prearranged 
marriage. His depressive state gradually deteriorated. 
Four month later he broke off his engagement. At that 
time he also had suicidal ideas and tried to commit 
suicide. One month later he visited our psychiatric 
clinic and was admitted to our psychiatric ward the 
same day. After admission, his HAMD score was evalu-
ated and a platelet [ 125I] LSD binding assay was per-
formed every week. After the start of treatment with 
an experimental new drug (double blind study, both 
active drugs), his depressive symptoms improved
initially, but from the sixth week of admission they 
became worse. Correlatively, the Bmax of platelet ["'I] 
LSD binding decreased at first and then increased. A 
comparison of the Bmax of [125I]LSD binding and the 
HAMD scores also demonstrated a significant linear 
correlation (r=0.71, p=0.02, Fig.10). 
 The significant linear correlation between the Bmax 
of ['25I] LSD binding and the HAMD scores in these 
cases suggests that there is a possible relationship be-
tween increased platelet 5-HT2A receptor concentrations 
and the severity of depressive symptoms in the clini-
cal course.
Discussion 
  In recent years, serotonin receptors were divided 
into 14 different subtypesincluding 5-HT2 family 
of receptors, 5-HT2A, 5-HT2B and 5-HT2C. There appears to 
be a striking similarity in the pharmacological character-
istics of platelet and brain 5-HT2A receptors2>,12>. In addi-
tion, 5-HT2A receptors are linked to the phosphoinocitide 
second messenger system in both platelets") and brain". 
And the nucleotide sequence of human platelet 5-HT2A 
cDNA is identical to that reported for the human fron-
tal cortex 5-HT2A receptor". These results suggest that 
the regulation of 5-HT2A receptors at the gene level 
may be the same both platelets and brain. In the pre-
sent study, we applied in vitro receptor 
autoradiography to characterize [ 125 I] LSD binding to 
human platelet pellet sections. The present method re-
vealed a single class of high affinity binding sites for 
 [ 125I] LSD in human platelets. Both ketanserin and 
spiperone, the 5-HT2A selective ligands, inhibited ["'I]-
LSD binding to human platelet pellets with high po-
tency (IC50 values of 0.15 and 0.19 nM, respectively), 
whereas 5-HT and paroxetine (selective 5-HT reuptake 
inhibitor) inhibited binding with a very low potency. 
These data confirmed that the binding sites of human 
platelet pellets labelled by [ 1251] LSD using this method 
revealed 5-HT2A receptors. This method required a 
much smaller volume of blood (5ml) than a classical 
membrane binding assay (30m1). 
In a comparison of [125I]LSD binding to human 
platelet pellets in patients with depressive disorder be-
fore treatment in this episode, in patients who had 
been drug free for at least six months, and in normal 
controls, Bmax was significantly higher in depressive 
patients before treatment than in the controls. Patients 
were considered to show over moderate severity by 
which showed 17-37 points (25.4±2.9, mean±SEM) in 
the HAMD (17 items). In the depressive group, the 
comparison of the Bmax of [125I]LSD binding for eight
depressive patients who had been free from 
psychotropic medication at least 6 months and the 
HAMD at the time of blood sampling before treatment 
demonstrated no significant correlation. The small 
number of depressive patients may have influenced 
this result. 
  We recorded the platelet 5-HT2A measurements and 
the scores on the HAMD repeatedly after treatment in 
two cases. The comparison of the Bmax of [ 1211 ]LSD 
binding and the HAMD demonstrated significant lin-
ear correlation in these cases (Fig.9, Fig.10). There is 
a possible relationship between the increased plate-
let 5-HT2A receptor concentrations and the symptoms 
of depression. In the first case (No.5) , the Bmax of 
[ 125 I] LSD binding showed gradual decreases, corre-
sponding to the decreased HAMD scores in response to 
antidepressants treatment. It was considered that the 
decreased numbers of platelet 5-HT2A receptors in re-
sponse to the antidepressants treatment might result 
in a down-regulation. In the second case (No.9), soon 
after the start of treatment with an experimental new 
drug(double blind study), the depressive symptoms 
began to improve, but after the sixth week, symptoms 
began to worse again. Correlatively, the Bmax de-
creased at first and then increased again. This could 
not be fully explained by the antidepressant treatment 
alone. 
 It is very interesting that the density of platelet 
5-HT2A receptors in depressive patients who had been 
free from psychotropic medication for at least 6 
months was higher than that in normal controls. This 
finding showing increased values for the density of 
platelet 5-HT2A receptors in depressive patients com-
pared to normal controls is in agreement with the 
study of Biegon et al'),", but in disagreement with 
those of Cowen et al.'), and McBride et al."', all of 
whom found similar mean values for the density of 
platelet 5-HT2A receptors in depressive patients and 
normal controls. On the other hand, Pandey et al." ),22) 
have showed increased platelet 5-HT2A receptors in sui-
cidal patients independent of psychiatric diagnosis. In 
our experiments there was no statistical difference be-
tween the depressive patients with suicidal behavior 
and the depressive patients without suicidal behavior. 
Discrepancies in the results of the platelet 5-HT2A re-
ceptor binding studies in depressive disorders may be 
a reflection of number of factors, including the effects 
of the length of the psychotropic medication free inter-
val on platelet 5-HT2A receptor binding201. In our ex-
periments, the drug-free interval of at least 6 months 
was longer than that in other studies. The effects of 
exposure to psychotropic medication on platelet 
5-HT2A receptor binding in our experiments, therefore
may be smaller than the effects observed in other 
studies. Other factors including patients sample size 
and depressive subtype(psychotic or nonpsychotic, 
with or without melancholia) may be considered. 
Platelet 5-HT2A receptors may be regulated by blood 
5-HT concentration, monoamine oxydase activities in 
platelets and plasma cortisol levels throughout the 
hypothalamic-pituitary-adrenal axis. It is suggested 
that a depressive state may be reflected by increased 
value for the density of platelet 5-HT2A receptors in de-
pressive patients through regulation by these factors. 
 The increased density of platelet 5-HT2A receptors in 
depressive disorder may reflect a hyperfunction of the 
central 5-HT2A receptors. We would suggest that the 
increased density of platelet 5-HT2A receptors may be 
a possible state marker in depressive disorder. This 
method could be very useful in clinical research for in-
vestigating the platelet 5-HT2A receptors as diagnostic 
and therapeutic markers in depressive disorders.
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